Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Trial of Selumetinib for the Prevention of Plexiform Neurofibroma Growth and Morbidity in Neurofibromatosis Type 1

NCT06188741 is registered in ClinicalTrials.gov with University of Alabama at Birmingham as lead sponsor.

NCT NCT06188741
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06188741 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Trial of Selumetinib for the Prevention of Plexiform Neurofibroma Growth and Morbidity in Neurofibromatosis Type 1
Lead sponsor
University of Alabama at Birmingham
Phase
Phase 2
Overall status
Recruiting
Start date
August 27, 2025
Completion date
September 1, 2032
Enrollment
200 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

neurofibromatosis 1, plexiform neurofibroma